A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-04-01
|
| Series: | Infectious Agents and Cancer |
| _version_ | 1818621740428820480 |
|---|---|
| author | Deeken John F Rudek Michelle A Moore Page C Aboulafia David Sullivan Ryan Gerecitano John Cianfrocca Mary Henry David Ratner Lee Dezube Bruce Mosby Kimberly Tibbals Melinda Little Richard F Ivy S P Mitsuyasu Ronald T |
| author_facet | Deeken John F Rudek Michelle A Moore Page C Aboulafia David Sullivan Ryan Gerecitano John Cianfrocca Mary Henry David Ratner Lee Dezube Bruce Mosby Kimberly Tibbals Melinda Little Richard F Ivy S P Mitsuyasu Ronald T |
| author_sort | Deeken John F |
| collection | DOAJ |
| first_indexed | 2024-12-16T18:14:05Z |
| format | Article |
| id | doaj.art-bb5bcdcc0bbb487996a075846b9fd3d2 |
| institution | Directory Open Access Journal |
| issn | 1750-9378 |
| language | English |
| last_indexed | 2024-12-16T18:14:05Z |
| publishDate | 2012-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj.art-bb5bcdcc0bbb487996a075846b9fd3d22022-12-21T22:21:42ZengBMCInfectious Agents and Cancer1750-93782012-04-017Suppl 1O1510.1186/1750-9378-7-S1-O15A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061Deeken John FRudek Michelle AMoore Page CAboulafia DavidSullivan RyanGerecitano JohnCianfrocca MaryHenry DavidRatner LeeDezube BruceMosby KimberlyTibbals MelindaLittle Richard FIvy S PMitsuyasu Ronald T |
| spellingShingle | Deeken John F Rudek Michelle A Moore Page C Aboulafia David Sullivan Ryan Gerecitano John Cianfrocca Mary Henry David Ratner Lee Dezube Bruce Mosby Kimberly Tibbals Melinda Little Richard F Ivy S P Mitsuyasu Ronald T A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 Infectious Agents and Cancer |
| title | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_full | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_fullStr | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_full_unstemmed | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_short | A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061 |
| title_sort | phase 1 pk study of sunitinib with highly active antiretroviral therapy haart in hiv patients with solid tumors aids malignancy consortium study 061 |
| work_keys_str_mv | AT deekenjohnf aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT rudekmichellea aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT moorepagec aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT aboulafiadavid aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT sullivanryan aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT gerecitanojohn aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT cianfroccamary aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT henrydavid aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ratnerlee aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT dezubebruce aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mosbykimberly aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT tibbalsmelinda aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT littlerichardf aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ivysp aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mitsuyasuronaldt aphase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT deekenjohnf phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT rudekmichellea phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT moorepagec phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT aboulafiadavid phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT sullivanryan phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT gerecitanojohn phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT cianfroccamary phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT henrydavid phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ratnerlee phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT dezubebruce phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mosbykimberly phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT tibbalsmelinda phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT littlerichardf phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT ivysp phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 AT mitsuyasuronaldt phase1pkstudyofsunitinibwithhighlyactiveantiretroviraltherapyhaartinhivpatientswithsolidtumorsaidsmalignancyconsortiumstudy061 |